Cargando…
Randomized trial of add‐on triheptanoin vs medium chain triglycerides in adults with refractory epilepsy
OBJECTIVE: To investigate the feasibility, safety, and tolerability of add‐on treatment of the triglycerides of heptanoate (triheptanoin) vs the triglycerides of octanoate and decanoate (medium chain triglycerides [MCTs]) in adults with treatment‐refractory epilepsy. METHODS: After an 8‐week prospec...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398112/ https://www.ncbi.nlm.nih.gov/pubmed/30868125 http://dx.doi.org/10.1002/epi4.12308 |
_version_ | 1783399530500194304 |
---|---|
author | Borges, Karin Kaul, Neha Germaine, Jack Kwan, Patrick O'Brien, Terence J. |
author_facet | Borges, Karin Kaul, Neha Germaine, Jack Kwan, Patrick O'Brien, Terence J. |
author_sort | Borges, Karin |
collection | PubMed |
description | OBJECTIVE: To investigate the feasibility, safety, and tolerability of add‐on treatment of the triglycerides of heptanoate (triheptanoin) vs the triglycerides of octanoate and decanoate (medium chain triglycerides [MCTs]) in adults with treatment‐refractory epilepsy. METHODS: After an 8‐week prospective baseline period, people with drug‐resistant epilepsy were randomized in a double‐blind fashion to receive triheptanoin or MCTs. Treatment was titrated over 3 weeks to a maximum of 100 mL/d to be distributed over 3 meals and mixed into food, followed by 12‐week maintenance before tapering. The primary aims were to assess the following: (a) safety by comparing the number of intervention‐related adverse events with triheptanoin vs MCT treatment and (b) adherence, measured as a percentage of the prescribed treatment doses taken. RESULTS: Thirty‐four people were randomized (17 to MCT and 17 to triheptanoin). There were no differences regarding (a) the number of participants completing the study (11 vs 9 participants), (b) the time until withdrawal, (c) the total number of adverse events or those potentially related to treatment, (d) median doses of oils taken (59 vs 55 mL/d, P = 0.59), or (e) change in seizure frequency (54% vs 102%, P = 0.13). Please note that people with focal unaware seizures were underrepresented in the triheptanoin treatment arm (P = 0.04). The most common adverse events were gastrointestinal disturbances (47% and 62.5% of participants). Five people taking on average 0.73 mL/kg body weight MCTs (0.64 mL/kg median) and one person taking 0.59 mL/kg triheptanoin showed >50% reduction in seizure frequency, specifically focal unaware seizures. SIGNIFICANCE: Add‐on treatment with MCTs or triheptanoin was feasible, safe, and tolerated for 12 weeks in two‐thirds of people with treatment‐resistant epilepsy. Our results indicate a protective effect of MCTs on focal unaware seizures. This warrants further study. |
format | Online Article Text |
id | pubmed-6398112 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63981122019-03-13 Randomized trial of add‐on triheptanoin vs medium chain triglycerides in adults with refractory epilepsy Borges, Karin Kaul, Neha Germaine, Jack Kwan, Patrick O'Brien, Terence J. Epilepsia Open Full‐length Original Research OBJECTIVE: To investigate the feasibility, safety, and tolerability of add‐on treatment of the triglycerides of heptanoate (triheptanoin) vs the triglycerides of octanoate and decanoate (medium chain triglycerides [MCTs]) in adults with treatment‐refractory epilepsy. METHODS: After an 8‐week prospective baseline period, people with drug‐resistant epilepsy were randomized in a double‐blind fashion to receive triheptanoin or MCTs. Treatment was titrated over 3 weeks to a maximum of 100 mL/d to be distributed over 3 meals and mixed into food, followed by 12‐week maintenance before tapering. The primary aims were to assess the following: (a) safety by comparing the number of intervention‐related adverse events with triheptanoin vs MCT treatment and (b) adherence, measured as a percentage of the prescribed treatment doses taken. RESULTS: Thirty‐four people were randomized (17 to MCT and 17 to triheptanoin). There were no differences regarding (a) the number of participants completing the study (11 vs 9 participants), (b) the time until withdrawal, (c) the total number of adverse events or those potentially related to treatment, (d) median doses of oils taken (59 vs 55 mL/d, P = 0.59), or (e) change in seizure frequency (54% vs 102%, P = 0.13). Please note that people with focal unaware seizures were underrepresented in the triheptanoin treatment arm (P = 0.04). The most common adverse events were gastrointestinal disturbances (47% and 62.5% of participants). Five people taking on average 0.73 mL/kg body weight MCTs (0.64 mL/kg median) and one person taking 0.59 mL/kg triheptanoin showed >50% reduction in seizure frequency, specifically focal unaware seizures. SIGNIFICANCE: Add‐on treatment with MCTs or triheptanoin was feasible, safe, and tolerated for 12 weeks in two‐thirds of people with treatment‐resistant epilepsy. Our results indicate a protective effect of MCTs on focal unaware seizures. This warrants further study. John Wiley and Sons Inc. 2019-02-22 /pmc/articles/PMC6398112/ /pubmed/30868125 http://dx.doi.org/10.1002/epi4.12308 Text en © 2019 The Authors. Epilepsia Open published by Wiley Periodicals Inc. on behalf of International League Against Epilepsy. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Full‐length Original Research Borges, Karin Kaul, Neha Germaine, Jack Kwan, Patrick O'Brien, Terence J. Randomized trial of add‐on triheptanoin vs medium chain triglycerides in adults with refractory epilepsy |
title | Randomized trial of add‐on triheptanoin vs medium chain triglycerides in adults with refractory epilepsy |
title_full | Randomized trial of add‐on triheptanoin vs medium chain triglycerides in adults with refractory epilepsy |
title_fullStr | Randomized trial of add‐on triheptanoin vs medium chain triglycerides in adults with refractory epilepsy |
title_full_unstemmed | Randomized trial of add‐on triheptanoin vs medium chain triglycerides in adults with refractory epilepsy |
title_short | Randomized trial of add‐on triheptanoin vs medium chain triglycerides in adults with refractory epilepsy |
title_sort | randomized trial of add‐on triheptanoin vs medium chain triglycerides in adults with refractory epilepsy |
topic | Full‐length Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398112/ https://www.ncbi.nlm.nih.gov/pubmed/30868125 http://dx.doi.org/10.1002/epi4.12308 |
work_keys_str_mv | AT borgeskarin randomizedtrialofaddontriheptanoinvsmediumchaintriglyceridesinadultswithrefractoryepilepsy AT kaulneha randomizedtrialofaddontriheptanoinvsmediumchaintriglyceridesinadultswithrefractoryepilepsy AT germainejack randomizedtrialofaddontriheptanoinvsmediumchaintriglyceridesinadultswithrefractoryepilepsy AT kwanpatrick randomizedtrialofaddontriheptanoinvsmediumchaintriglyceridesinadultswithrefractoryepilepsy AT obrienterencej randomizedtrialofaddontriheptanoinvsmediumchaintriglyceridesinadultswithrefractoryepilepsy |